Nine health-care stocks have more than doubled in price this year, but still have more than 100% upside potential, according to analysts. All have a "buy" or equivalent rating, and every single one expects the stock to more than double over the next 12 months. The median average price target of $66.50 from eight analysts points to a 252% upside potential over the next 12 months. Benitec is expected to rise by 104% over the next 12 months, according to the median price target of five analysts. Humacyte has doubled this year, and analysts expect it to double again over the next 12 months.

---

Persons: Benitec, Arcutis, Stocks, Rezolute Rezolute, Trevi, Arcutis Biotherapeutics, Humacyte Organizations: CNBC Pro, Nasdaq, Jasper Therapeutics, Corbus Pharmaceuticals, Rezolute, Trevi Therapeutics, Delcath Systems, Precision Medicines, Jasper Therapeutics Jasper Therapeutics, Pharmaceuticals Corbus Pharmaceuticals, Trevi Therapeutics Trevi Therapeutics, Systems Delcath Systems, Praxis, Medicines Locations: Jasper, Jasper Therapeutics Jasper, Massachusetts, California, U.S, Europe, Australia, Hayward , California